1. Home
  2. CSBR vs ANVS Comparison

CSBR vs ANVS Comparison

Compare CSBR & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Champions Oncology Inc.

CSBR

Champions Oncology Inc.

HOLD

Current Price

$5.29

Market Cap

81.0M

Sector

Health Care

ML Signal

HOLD

Logo Annovis Bio Inc.

ANVS

Annovis Bio Inc.

HOLD

Current Price

$1.39

Market Cap

76.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSBR
ANVS
Founded
1985
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
81.0M
76.6M
IPO Year
2015
2019

Fundamental Metrics

Financial Performance
Metric
CSBR
ANVS
Price
$5.29
$1.39
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$13.50
AVG Volume (30 Days)
6.4K
778.8K
Earning Date
03-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
39.39
EPS
N/A
N/A
Revenue
$2,900,000.00
N/A
Revenue This Year
$4.84
N/A
Revenue Next Year
$11.51
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.83
$1.32
52 Week High
$8.74
$5.50

Technical Indicators

Market Signals
Indicator
CSBR
ANVS
Relative Strength Index (RSI) 56.18 27.56
Support Level $4.83 N/A
Resistance Level $6.31 $2.02
Average True Range (ATR) 0.20 0.11
MACD 0.06 -0.03
Stochastic Oscillator 83.82 10.34

Price Performance

Historical Comparison
CSBR
ANVS

About CSBR Champions Oncology Inc.

Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.

About ANVS Annovis Bio Inc.

Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.

Share on Social Networks: